Skip to Content

Rule

Control of Communicable Diseases; Restrictions on African Rodents, Prairie Dogs, and Certain Other Animals

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 7825

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Interim final rule; supplement and partial reopening of comment period.

SUMMARY:

The Food and Drug Administration (FDA) is reopening the comment period for the interim final rule on the capture, transport, sale, barter, exchange, distribution, and release of African rodents, prairie dogs, and certain other animals, which was published in the Federal Register of November 4, 2003 (68 FR 62353). FDA is taking this action because it is adding new information, primarily in the form of peer-reviewed scientific literature, to the administrative record. FDA is reopening the comment period for 30 days for the sole purpose of inviting public comments on the information being added to the administrative record.

DATES:

Submit written or electronic comments by March 23, 2007.

ADDRESSES:

You may submit comments, identified by Docket No. 2003N-0400 and/or RIN number 0910-ZA21, by any of the following methods:

Electronic Submissions

Submit electronic comments in the following ways:

Written Submissions

Submit written submissions in the following ways:

  • FAX: 301-827-6870.
  • Mail/Hand delivery/Courier [For paper, disk, or CD-ROM submissions]: Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

To ensure more timely processing of comments, FDA is no longer accepting comments submitted to the agency by e-mail. FDA encourages you to continue to submit electronic comments by using the Federal eRulemaking Portal or the agency Web site, as described previously, in the ADDRESSES portion of this document under Electronic Submissions.

Instructions: All submissions received must include the agency name and docket number and Regulatory Information Number (RIN) for this rulemaking. All comments received may be posted without change to http://www.fda.gov/​ohrms/​dockets/​default.htm, including any personal information provided. For additional information on submitting comments, see the “Comments” heading of the SUPPLEMENTARY INFORMATION section of this document.

Docket: For access to the docket to read background documents or comments received, go to http://www.fda.gov/​ohrms/​dockets/​default.htm and insert the docket number, found in brackets in the heading of this document, into the “Search” box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Philip L. Chao, Office of Policy and Planning (HF-23), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-0587.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Background

In the Federal Register of November 4, 2003 (68 FR 62353), the Centers for Disease Control and Prevention (CDC) and FDA issued an interim final rule to establish new restrictions and modify existing restrictions on the import, capture, transport, sale, barter, exchange, distribution, and release of African rodents, prairie dogs, and certain other animals in order to prevent the spread of monkeypox, a communicable disease, in the United States. The CDC regulation is codified at 42 CFR 71.56, and FDA's regulation is codified at 21 CFR 1240.63.

Since the publication of the interim final rule in the Federal Register, additional scientific information has appeared regarding the 2003 monkeypox outbreak. In general, the scientific information adds to our knowledge about the 2003 monkeypox outbreak in the United States, including information about the virus and how the disease affected or affects humans and animals.

FDA is adding the following documents to the administrative record for the interim final rule:

1. Anderson, M.G., et al., “A Case of Severe Monkeypox Virus Disease in an American Child: Emerging Infections and Changing Professional Values,” Pediatric Infectious Disease Journal, 2003; 22:1093-1096.

2. Bernard, S.M. and Anderson, S.A., “Qualitative Assessment of Risk for Monkeypox Associated with Domestic Trade in Certain Animal Species, United States” Emerging Infectious Diseases, 2006; 12: 1827-1833.

3. Di Giulio, D.B. and Eckburg, P.B., “Human Monkeypox: An Emerging Zoonosis,” Lancet Infectious Diseases, 2004; 4:15-25.

4. Fleischauer, A.T., et al., “Evaluation of Human-to-Human Transmission of Monkeypox from Infected Patients to Health Care Workers,” Clinical Infectious Diseases, 2005; 40:689-694.

5. Guarner, J., et al., “Monkeypox Transmission and Pathogenesis in Prairie Dogs,” Emerging Infectious Diseases, 2004; 10:426-431.

6. Hammarlund, E., et al., “Multiple Diagnostic Techniques Identify Previously Vaccinated Individuals With Protective Immunity Against Monkeypox,” Nature Medicine, 2005; 11:1005-1011.

7. Huhn, G.D., et al., “Clinical Characteristics of Human Monkeypox, and Risk Factors for Severe Disease,” Clinical Infectious Diseases, 2005; 41:1742-1751.

8. Huhn, G.D., et al., “Monkeypox in the Western Hemisphere,” New England Journal of Medicine, 2004; 350:1790-1791.

9. Jamieson, D.J., et al., “Emerging Infections and Pregnancy: West Nile Virus, Monkeypox, Severe Acute Respiratory Syndrome, and Bioterrorism,” Clinics in Perinatology, 2005; 32:765-776.

10. Kile, J.C., et al., “Transmission of Monkeypox Among Persons Exposed to Infected Prairie Dogs in Indiana in 2003,” Archives of Pediatrics and Adolescent Medicine, 2005; 159:1022-1025.

11. Likos, A.M., et al., “A Tale of Two Clades: Monkeypox Viruses,” Journal of General Virology, 2005; 86:2661-2672.

12. Nalca, A., et al., “Reemergence of Monkeypox: Prevalence, Diagnostics, and Countermeasures,” Clinical Infectious Diseases, 2005; 41:1765-1771.

13. Reed, K.D., et al., “The Detection of Monkeypox in Humans in the Western Hemisphere,” New England Journal of Medicine, 2004; 350:342-350.

14. Reynolds, Gretchen, “Why Were Doctors Afraid to Treat Rebecca McLester?” New York Times, April 18, 2004.Start Printed Page 7826

15. Reynolds, M.G., et al., “Clinical Manifestations of Human Monkeypox Influenced by Route of Infection,” Journal of Infectious Diseases, 2006; 773-780.

16. Sejvar, J.J., et al., “Human Monkeypox Infection: A Family Cluster in the Midwestern United States,” Journal of Infectious Diseases, 2004; 190:1833-1840.

17. Xiao, S., et al., “Experimental Infection of Prairie Dogs with Monkeypox Virus,” Emerging Infectious Diseases, 2005; 11:539-545.

II. Comments

Through this document, FDA is announcing the addition of the previous materials to the administrative docket and inviting comment limited to these publications. FDA believes that a 30-day comment period is sufficient in this case, as the agency is specifically limiting its reopening of the comment period to comments on how the agency should consider the information being added to the administrative docket in relation to FDA's interim final rule. Comments are invited, and will be considered, only to the extent they are focused on the specific information being added to the record of FDA's interim final rule.

Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding the documents listed above. Submit a single copy of electronic comments or two copies of any mailed comments, except that individuals may submit one paper copy. Comments should be identified with the docket number found in brackets in the heading of this document. Received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

Start Signature

Dated: February 9, 2007.

Jeffrey Shuren,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. E7-2857 Filed 2-20-07; 8:45 am]

BILLING CODE 4160-01-S